We are excited to announce that Allogenetics GmbH, a pioneering company dedicated to revolutionizing organ transplantation technology, has successfully secured €3.4 million in funding. This significant investment is a testament to the confidence that renowned investors have in Allogenetics’ innovative approach to addressing the ongoing challenges in organ transplantation. With this new funding, Allogenetics aims to expedite the development of groundbreaking solutions designed to enhance donor-recipient compatibility, reduce organ rejection rates, and ultimately save lives. Our team is committed to leveraging cutting-edge research and technology to create a future where organ transplants are not only more successful but also more accessible to those in need. The funds will be directed toward advancing our proprietary methodologies, intensifying our research and development efforts, and expanding our clinical trials. As we embark on this exciting new phase of growth, Allogenetics is poised to make a significant impact on the global transplantation landscape. We invite you to stay updated on our progress, and for those interested in learning more about our innovative initiatives, please do not hesitate to contact us for further information. Together, we can reshape the future of organ transplantation and improve outcomes for countless patients around the world.

Allogenetics Secures $3.4 Million Seed Round Investment to Revolutionize Organ Transplantation Technology
Get the full Allogenetics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Centricity WealthTech
Founded in January 2022, Centricity helps empower finance and investment professionals aspiring to establish their independent practices. The platform aims to deliver a comprehensive SAAS based investment management platform including digital transactional capabilities for a diversified product suite. Wealth management professionals prefer focusing on their clients’ interests and not their employers ever-changing priorities. Also, clients want stability and not a relentless institutional product push. We are looking to bring in consistency of the family office experience for a spectrum of investors across emerging affluent, affluent and high net worth categories. We are boutique by design and an institution by default.
$30.0M Series a
today

MigmaAI
Create, design and send on-brand emails in seconds.
$330.0K Pre-seed
today

Multiverse
Multiverse is the upskilling platform for AI and tech adoption. We’ve built a new model for transforming today’s workforce by combining expert human coaching with AI. Our learning drives real business impact and helps organisations close critical skills gaps - especially in data, AI and all things tech. We’ve already partnered with over 1,500 global organisations to transform their workforce through tech skills. Trusted by Microsoft, Mars, John Lewis Partnership and many more to upskill their team and unlock people’s potential and output. In 2022, we raised our $220m Series D funding - one of the largest venture rounds in EdTech history. We’re proud to be backed by some of the world’s biggest investors, including General Catalyst, Lightspeed Venture Partners and StepStone Group.
$70.0M Unknown
today

SWELL Sculpture Festival
SWELL Sculpture Festival (SWELL) is a multifaceted arts organisation that connects people, art, and place, based in Currumbin, Gold Coast, Queensland. Since 2003 SWELL has exhibited 873 Sculptures in the main exhibition on Currumbin Beach with a portfolio value worth $15.5M.
$5.5K Grant
today

Parcel Health
Healthcare and pharmacies' supply chain runs on expensive plastic. Billions of units of disposable, single-use supplies and packaging — most of it never questioned, never redesigned, never replaced. Paid for at a premium to budgets and to the environment. Until now. Parcel Health is reimagining healthcare supplies, creating products that can protect people and preserve the planet, all at an affordable price point. Tully Tube® is the world's first and only paper pill bottle that meets U.S. regulatory requirements. It is trusted by leading hospital health-systems like Dartmouth-Hitchcock Health System, Allegheny Health Network, and Wellstar Health System. This is just the beginning. Parcel Health is building a future where healthcare supplies are safer for patients, better for the planet, and easier on budgets.
$1.2M Seed
today
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Parcel Health United States | Seed | $1.2M | today |
| 2 | ![]() Envoke Canada | Seed | $1.6M | today |
| 3 | ![]() H2CHP Limited United Kingdom | Seed | $1.5M | today |
| 4 | ![]() Synthetic Brazil | Seed | $10.0M | 1d ago |
| 5 | ![]() harva. (formerly Supply Pay) United States | Seed | $113.0M | 1d ago |



.png&w=3840&q=75)